From CNBC: 2024-08-20 07:56:31

Eli Lilly’s weight loss drug reduces Type 2 diabetes risk by 94%. Patients on the highest dose lost 22.9% body weight over 176 weeks. More than 1 in 3 Americans have prediabetes, can be reversed with lifestyle changes. GLP-1 drugs like Zepbound and Mounjaro show potential long-term benefits. Side effects of Zepbound are generally mild.



Read more at CNBC: Eli Lilly weight loss drug cuts risk of developing diabetes in trial